Early Referral for Patients With IBD Failing Conventional Therapies

Background

Questions

Red Flags Index for CD (IOIBD)

How Long Is the Delay?

Why Is Diagnosis Delayed?

Why Does Delay Matter?

If IBD Is Progressive, a Window of Opportunity May Exist: UC

If IBD Is Progressive, a Window of Opportunity May Exist: CD

Step Up vs Top Down: Early Combined Therapy Improves Outcomes

REACT: Study Results

REACT-2: Ongoing Study Using an Enhanced Treatment Algorithm

Early Intervention With Biologics Appears to Improve Outcomes

Clinical Practice: Expert Advice

CALM: Treatment Escalation Based on Clinical Symptoms Combined With Biomarkers (Tight Control) is Better vs Symptoms Alone (Clinical Management)

Clinical Practice: Expert Advice (Cont)

Clinical Practice: Expert Advice (Cont)

EXTEND: Early Use of Continuous Anti-TNF Therapy Improves Endoscopic Outcomes in CD

Early Use of Vedolizumab and Ustekinumab

US VICTORY Consortium for IBD: Cohort Study

LOVE-CD: Prospective Study Comparing Early vs Late Use of Vedolizumab in Patients With CD

Identifying Patients Who May Benefit From Early Use of Biologics

Managing the Individual Patient With IBD

Final Thoughts

Abbreviations